Joseph G. Oliveto, M.B.A
Interim Chief Executive Officer
Key Compounds: Pegasys®, Copegus®, Xenical®
Mr. Oliveto joined Chelsea following a two-year assignment as Executive in Residence at Pappas Ventures, a life sciences venture capital firm. Prior to Pappas Ventures, he served in a number of progressively senior positions at Hoffmann-La Roche, most recently as a the Global Alliance Director in for Roche's licensing organization. Previous experience at Roche includes clinical development, project management, manufacturing process improvement and global business. During his tenure, he played an integral part in the success of multiple NDA filings, developed comprehensive launch programs, including those for both Pegasys and CoPegus, and closed multiple licensing deals.
Mr. Oliveto obtained a BA in Chemistry and an MBA from Rutgers University.
L. Arthur Hewitt, Ph.D.
Chief Scientific Officer
Key Compounds: Neupogen®, Infergen®
Dr. Hewitt has over 30 years of pharmaceutical industry experience working for Abbott Laboratories, Parke-Davis, Janssen Pharmaceuticals and Amgen. While at Amgen he was the Head of Clinical Research and Regulatory Affairs in Canada. During his years at Amgen, Dr. Hewitt oversaw the establishment of thirteen individual IND research programs (in hematology, oncology, neurology, infectious disease and inflammation), the approval process for three NCEs (Neupogen, Infergen, Stemgen) as well as six supplementary approvals for additional claims for the use of Neupogen.
Dr. Hewitt obtained his Ph.D. in Pharmacology from the Medical School at the University of Montreal
J. Nick Riehle, M.B.A
Vice President, Administration and CFO
Mr. Riehle has over 25 years of business and management experience with both large fortune 500 companies and start-up ventures. He hasheld senior positions at HAHT Commerce and Nortel Networks. In addition he has had significant success with regards to venture financing, growing business volume and improving profitability.
Mr. Riehle earned his Bachelor of Commerce from McGill University, his MBA from York University and a Certified Management Accountant (CMA) designation in Ontario, Canada.
William D. Schwieterman, M.D.
Chief Medical Officer
Dr. Schwieterman joined the company as an employee and officer in October 2009 after serving for more than a year on our Board of Directors and several years as a consultant and member of the company’s Scientific Advisory Board. He is a rheumatologist and board-certified internist who was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules. Dr. Schwieterman helped author the FDA's "Good Review Practices" for investigational products, and was instrumental in developing several guidance documents for the industry. Since leaving the FDA, he has acted as an independent consultant to biotechnology and pharmaceutical companies, focusing on clinical drug development and regulatory matters.
Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati.
Michael J. Roberts, Ph.D. Vice President, Business Development
Key Compounds: Macugen ®, PEG-Intron ®, Neulasta ®, OMONTYS ®, Cimzia ®
Dr. Roberts joined Chelsea from Nektar Therapeutics where he was Director of Business Development for their Molecule Engineering technology. Prior to this he was Manager of Biopharmaceutical Research at Shearwater Corporation where he led and was successful in the development of preclinical drug candidates from initial stages of research through Phase I clinical study, including drug candidates such as naloxegol.
Dr. Roberts obtained his Ph.D. in Materials Science from the University of Alabama in Huntsville and B.S. in Chemical Engineering from Pennsylvania State University.
